Jinwon Life Sciences Subsidiary VGXI Selected as Member of US BARDA Rapid Response Collaboration Organization

Jinwon Life Sciences announced on the 31st that its subsidiary VGXI, a leading contract development and manufacturing organization (CDMO) in the field of nucleic acid biopharmaceuticals such as gene therapy, DNA vaccines, and RNA drugs, has been selected as a member of the Rapid Response Vaccine Partnership (RRPV) supported by the Biomedical Advanced Research and Development Authority (BARDA) under the U.S. Department of Health and Human Services.

The company stated, “VGXI possesses the largest plasmid DNA production capacity in the world and has over 20 years of experience in plasmid DNA manufacturing,” adding, “The Rapid Response Vaccine Partnership (RRPV) aims to accelerate the development of products and technologies to address evolving diseases, including pandemics, emerging infectious diseases, and other biological threats.”

Park Young-geun, CEO of Jinwon Life Sciences, said, “We are honored to be selected as a member of the Rapid Response Vaccine Partnership (RRPV),” emphasizing, “Based on our achievements in producing vaccines for infectious diseases such as influenza, Ebola, MERS, and COVID-19, we have gained the opportunity to participate in future pandemic responses alongside other members of the RRPV.”

Meanwhile, the Rapid Response Vaccine Partnership (RRPV) recently supported Moderna Therapeutics with approximately 240 billion KRW to rapidly develop an mRNA-based pandemic influenza vaccine.